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Abstract
Objective: Both variations in the interleukin-10 (IL10) gene and environmental factors are thought to influence
inflammation and gastric carcinogenesis. Therefore, we investigated the associations between IL10 polymorphisms,
Helicobacter pylori (H. pylori) infection, and smoking in noncardia gastric carcinogenesis in Koreans.
Methods: We genotyped three promoter polymorphisms (-1082A.G, -819T.C, and -592 A.C) of IL10 in a case-control
study of 495 noncardia gastric cancer patients and 495 sex- and age-matched healthy controls. Multiple logistic regression
models were used to detect the effects of IL10 polymorphisms, H. pylori infection, and smoking on the risk of gastric cancer,
which was stratified by the histological type of gastric cancer.
Results: The IL10-819C and -592C alleles were found to have complete linkage disequilibrium, and all three IL10
polymorphisms were associated with an increased risk of intestinal-type noncardia gastric cancer. These associations were
observed only in H. pylori-positive subjects and current smokers. A statistically significant interaction between the IL10-592
genotype and H. pylori infection on the risk of intestinal-type gastric cancer was observed (P for interaction =0.047). In
addition, H. pylori-positive smokers who were carriers of either the IL10-1082G (OR [95% CI] =17.76 [6.17251.06]) or the
-592C (OR [95% CI] =8.37 [2.79225.16]) allele had an increased risk of intestinal-type gastric cancer compared to H. pylori-
negative nonsmokers homozygous for IL10-1082A and -592A, respectively. The interaction between the IL10-1082
polymorphism and the combined effects of H. pylori infection and smoking tended towards significance (P for interaction
=0.080).
Conclusions: Inflammation-related genetic variants may interact with H. pylori infection and smoking to increase the risk of
noncardia gastric cancer, particularly the intestinal-type. These findings may be helpful in identifying individuals at an
increased risk for developing noncardia gastric cancer.
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Introduction
Gastric cancer is the second most common cause of cancer
mortality globally and the prevalence of gastric cancer is higher in
Asians than in Western populations [1]. Numerous studies have
supported the concept that gastric inflammation is a critical
component of tumor development [2,3]. H. pylori is a strong risk
factor for gastric cancer, likely due to the extensive inflammation
in the stomach mucosa caused by this bacteria [4]. However,
considering that only a small portion of H. pylori-infected subjects
eventually develop gastric cancer, the pathway from H. pylori
infection to carcinogenesis may be affected by several factors,
including H. pylori strain variability, lifestyle (e.g., smoking, low
vegetable/fruit consumption, high salt intake), and host genetics
[5,6].
In chronic gastric inflammation, activated neutrophils and
mononuclear cells produce different types of cytokines that are
crucial in regulating inflammation [7,8]. Altered cytokine levels
have been observed during tumor initiation and promotion in the
stomach [9,10]. Interleukin-10 (IL10) is a multifunctional anti-
inflammatory cytokine that downregulates cell-mediated immune
responses and cytotoxic inflammatory responses. Three polymor-
phic promoter variants, located at positions -1082 (A.G), -819
(T.C), and -592 (A.C), have been identified in the IL10 gene. It
has been reported that these variants of IL10 are associated with
increased IL10 production [11–13] and an elevated risk of gastric
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29643cancer [14,15]. Furthermore, environmental factors, such as
cigarette smoking, may alter cytokine expression in a manner
more favorable for the development of gastric inflammation and
carcinogenesis [16]. Therefore, inflammation-related polymor-
phisms may interact with environmental factors in the develop-
ment of gastric cancer.
Although many studies have investigated the roles of IL10
promoter polymorphisms and the risk of gastric cancer, the findings
remain inconclusive, possibly due to differences in study design
and/or ethnic differences in the populations studied [14,15,17–19].
Furthermore,gastriccancersthatdifferinanatomiclocationand/or
histological type have different clinicopathological characteristics
[3,6]. H. pylori infection and chronic inflammation have been more
closely linked with noncardia gastric cancer than with cardia gastric
cancer and may induce the histological progression to gastric cancer
[3]. In addition, the impact of genetic and environmental factors
may differ by the histological type of gastric cancer [6]. Therefore,
the present study aimed to investigate the effects of IL10 genetic
variants, H. pylori infection, cigarette smoking, and their interactions
on the risk of noncardia gastric carcinogenesis. We also examined
the differential effects of these factors according to the histological
type of gastric cancer.
Materials and Methods
Study Population
This study was a hospital-based case-control study. A total of 797
patients with noncardia gastric cancer were recruited from the
National Cancer Center Hospital in Goyang between 2003 and
2007. Only histologically-confirmed adenocarcinoma patients were
included in this study, and other types of neoplasms found in the
stomach (e.g., MALT lymphomas, other types of primary gastric
lymphoma, gastrointestinal stromal tumors, carcinoid tumors, or
adenomas) were excluded. Nine hundred thirty healthy controls
who underwent upper endoscopy at the same institution for gastric
cancer screening in the National Cancer Screening Program in
Korea and were without significant gastrointestinal symptoms were
recruited in 2007. All cases and controls were of Korean ancestry.
For both gastric cancer cases and controls, we excluded subjects
who had a history of other malignant neoplasms, had a history of
previousH.pyloritreatment,had notreceivedanH.pylorievaluation,
or were lacking in information about their genetic background.
Cases and controls were frequency-matched by age (within 5-
years) and sex. In total, 495 cases and 495 controls were used for
the final analyses. Noncardia gastric cancer patients were classified
into two subgroups (intestinal-type and diffuse-type) based on the
histopathology according to the Lauren classification [20]. The
clinical information and genetic materials were obtained under the
approval of the Institutional Review Board of the National Cancer
Center in Korea, and written informed consent was obtained from
each subject.
Data Collection
The questionnaire data and blood samples were obtained at the
initial recruitment of both cases and controls. All participants were
asked to complete a self-administered questionnaire about their
sociodemographic characteristics (e.g., age, family history of
gastric cancer, income, and education), smoking habits, alcohol
intake, and personal medical history. H. pylori infection status was
determined by a rapid urease test and a histological evaluation.
The rapid urease test was performed according to the manufac-
turer’s instructions (Pronto Dry. Medical Instruments Corpora-
tion, Solothurn, Switzerland). For the histological evaluation of H.
pylori, biopsy specimens were obtained from three different areas,
the gastric antrum, the corpus lesser curvature, and the corpus
greater curvature, to increase the sensitivity of the procedure. Two
pieces of biopsy specimens were obtained from each site, and
Wright-Giemsa staining was performed on the biopsy samples to
determine if H. pylori was present.
Genotyping of the IL10 promoter (-1082/-819/-592) was
conducted and interpreted by a researcher blinded to case/control
status. Briefly, genomic DNA was prepared from peripheral blood
samples with an automatic DNA extraction system (BioRobot
M48 Workstation, Qiagen, Inc., Valencia, CA) following the
manufacturer’s instructions, and the purity and concentration of
isolated DNA were determined using picogreen (Molecular
Probes, Inc., Eugene, OR). A total of 10 ng per sample was used
for genotype analysis. Genotyping for the three SNPs was
performed by the iPLEX Gold assay (Sequenom, San Diego,
CA), which is based on MALDI-TOF spectrometry, per the
manufacturer’s protocol, and the resulting genotype data were
collected by Typer v4.0 (Sequenom). To ensure quality control,
subsets of the samples were run as duplicates and 5% of the wells
in a 384-well plate were used as negative controls to monitor for
contamination. For all results, genotype clusters were examined
manually for their fitness.
Statistical Analysis
The demographic characteristics, environmental factors, and
gene frequencies of IL10 in patients and controls were compared
using x
2 statistics. The Hardy-Weinberg equilibrium of genotype
frequencies in the controls was tested with the x
2 test. The
association between IL10 genetic variants (-1082/-819/-592) and
the risk of gastric cancer was estimated by multivariate logistic
regression with adjustments for age, sex, H. pylori infection,
smoking, alcohol consumption, income, and education and was
expressed as odds ratios (ORs) with 95% confidence intervals
(CIs). Haplotype analyses were also conducted. IL10 haplotypes
were constructed based on the frequencies of three SNPs (-1082/
-819/-592) in this study population. These polymorphisms were
found to be in strong linkage disequilibrium, and three of the eight
possible haplotypes (GCC, ACC, ATA) segregate in the Korean
population. We defined the more common homozygous geno-
type/haplotype in the control subjects as the reference genotype/
haplotype. The effects of H. pylori infection and smoking on the
association between genetic variants and the risk of gastric cancer
were examined in a subgroup analysis by H. pylori infection status
(H. pylori-positive/H. pylori-negative) or smoking status (non-
smoker/past smoker/current smoker). In addition, to investigate
the combined effects of H. pylori infection and smoking on the
association between genetic variants and the risk of gastric cancer,
subjects were grouped according to their dichotomized H. pylori
infection (H. pylori-positive/H. pylori-negative) and smoking
(smokers (all subjects who had ever smoked were classified as
smokers)/non-smokers) status. Data were stratified by the
histological type of gastric cancer (intestinal-type/diffuse-type).The
significance of the interactions between genetic variants and
environmental risk factors was assessed with the likelihood ratio
test, which compared the model with the interaction term with the
one that only contained the main effects. All statistical analyses
were performed with SAS 9.1 software (SAS Institute Inc. Cary,
NC). Two-sided P-values less than 0.05 were regarded as
statistically significant.
Results
The demographics of the study subjects are shown in Table 1.
No differences between cases and controls in the distribution of
Risk Factors for Gastric Cancer
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cases were more likely to have H. pylori infection (P,0.001), more
likely to smoke (P,0.001), and less likely to drink alcoholic
beverages (P=0.027) than controls. In addition, cases also had a
lower mean income (P=0.017) and less education (P,0.001) than
controls. With regard to genetic frequencies, no significant
differences between cases and controls in the frequencies of the
IL10-1082/-819/-592 polymorphisms were present. IL10-819 and
IL10-592 were found to be in complete linkage disequilibrium.
To determine whether genetic susceptibility to noncardia gastric
cancer was present, the association between IL10 variants and the
risk of noncardia gastric cancer stratified by histological type was
investigated (Table 2). The results of a multivariate regression
model revealed that IL10-1082G (OR [95% CI] =1.69
[1.0622.69]) and -592C (OR [95% CI] =1.55 [1.1022.18])
carriers had a higher risk of intestinal-type gastric cancer than
subjects homozygous for the IL10-1082A allele and -592A allele,
respectively. In addition, carriers of the GCC haplotype had an
increased risk of intestinal-type gastric cancer compared to ATA
haplotype carriers (OR [95% CI] =1.64 [1.0622.54]). We also
examined the association between IL10 genetic variants and the
risk of gastric cancer after stratifying noncardia gastric cancer by
stage (data not shown). However, we did not find any differences
in the risk of gastric cancer between the disease stages.
Next, we investigated the effects of H. pylori infection status on
the association between IL10 genetic variants and the risk of
noncardia gastric cancer (Table 3). H. pylori-infected participants
had an increased risk of gastric cancer compared to H. pylori-
negative participants (OR [95% CI] =4.30 [3.0226.11]). The
association between H. pylori infection and the risk of gastric cancer
was stronger among genetic variant carriers, particularly among
intestinal-type gastric cancer patients. The interaction between the
IL10-592 genetic variant and H. pylori infection on the risk of
intestinal-type gastric cancer was statistically significant (P for
interaction =0.047).
We also examined the effects of smoking on the association
between IL10 genetic variants and the risk of noncardia gastric
cancer (Table 4). The association between current smoking and an
increased risk of gastric cancer was stronger amongst IL10-1082G
carriers and IL10-592C carriers. Current smokers that carried the
IL10-1082G (OR [95% CI] =8.72 [3.64220.91]) and -592C (OR
[95% CI] =5.40 [2.69210.84]) alleles had an increased risk of
intestinal-type gastric cancer compared to nonsmokers homozy-
gous for IL10-1082A and -592A, respectively. However, no
statistically significant interactions between IL10 genetic variants
and cigarette smoking on the risk of gastric cancer were observed.
To evaluate the interactions between environmental factors and
genetic susceptibility, the combined effects of H. pylori infection
and smoking on the association between IL10 variants and the risk
of noncardia gastric cancer were investigated (Figure 1). Smoking
seemed to have no effect in the absence of H. pylori infection, but
when the data were stratified by genetic variants and histological
type, H. pylori-positive smokers that carried either the IL10-1082G
(OR [95% CI] =17.76 [6.17251.06]) or -592C (OR [95% CI]
=8.37 [2.79225.16]) allele had an increased risk of intestinal-type
gastric cancer compared to H. pylori-negative nonsmokers
homozygous for IL10-1082A allele or -592A allele, respectively.
The association between intestinal-type gastric cancer and the
combined effects of H. pylori infection and smoking was stronger
among carriers of the IL10 genetic variants. The test for
interaction between the IL10-1082 polymorphisms and the
combined effects of H. pylori infection and smoking trended
towards significance (P for interaction =0.080).
Discussion
A number of studies have reported an association between IL10
promoter polymorphisms (-1082G/-819C/-592C) and the risk of
gastric cancer, but these findings have been inconsistent
[14,15,17–19]. In accord with our findings, recent meta-analyses
suggested that Asian carriers of the promoter polymorphisms of
IL10 may be associated with an increased risk of gastric cancer
[21,22]. However, some studies, mostly studies conducted in
Table 1. Characteristics of the Study Subjects*.
Gastric Cancer
Cases (n=495)
Controls
(n=495) P-value
Age (years), mean 6 SD 54.968.4 54.367.4 0.208
Male 337 (68.1) 337 (68.1) 1.000
Family history of gastric cancer 220 (44.4) 225 (45.5) 0.749
H. pylori infection (positive) 443 (89.9) 329 (66.6) ,0.001
Smoking status
Non-smoker 183 (37.0) 208 (42.0) ,0.001
Past smoker 108 (21.8) 158 (31.9)
Current smoker 204 (41.2) 129 (26.1)
Alcohol consumption
Non-drinker 167 (33.8) 147 (29.7) 0.027
Past drinker 50 (10.1) 33 (6.7)
Current drinker 277 (56.1) 315 (63.6)
Income
Low 205 (41.4) 165 (33.3) 0.017
Medium 242 (48.9) 286 (57.8)
High 48 (9.7) 44 (8.9)
Education (years)
,12 231 (46.7) 145 (29.3) ,0.001
$12 264 (53.3) 350 (70.7)
IL10-1082
AA 416 (84.0) 435 (87.9) 0.198
AG 72 (14.6) 56 (11.3)
GG 7 (1.4) 4 (0.8)
IL10-819
TT 231 (46.7) 248 (50.1) 0.325
CT 214 (43.2) 191 (38.6)
CC 50 (10.1) 56 (11.3)
IL10-592
AA 231 (46.7) 248 (50.1) 0.325
CA 214 (43.2) 191 (38.6)
CC 50 (10.1) 56 (11.3)
Histological type of gastric cancer
Intestinal 253 (51.1) -
Diffuse 214 (43.2) -
Mixed 28 (5.7) -
Stage of gastric cancer
Early gastric cancer
{ 279 (56.4) -
Advanced gastric cancer{ 216 (43.6) -
*Results presented as n (%) unless otherwise indicated.
{Depth of tumor invasion limited to mucosa or submucosa.
{Depth of tumor invasion involved the proper muscle layer or beyond.
doi:10.1371/journal.pone.0029643.t001
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Differences in the number of patients enrolled, study design,
patient age at diagnosis, and genotyping methods may contribute
to the differences in the results of such studies [9]. In addition,
racial differences in the distribution of the IL10 genotypes may also
affect the findings of the studies. Compared to other populations,
the frequency of the IL10 polymorphisms is significantly lower in
Asians [24]. This difference may be clinically relevant for
susceptibility to gastric cancer and may, in part, explain the
different incidences of gastric cancer in Caucasians and Asians
[24].
IL10 genetic variants have been proposed to be associated with
higher IL10 production [11–13]. IL10 levels are elevated in gastric
mucosa infected with H. pylori and are higher in patients that have
severe chronic inflammation [25]. Furthermore, IL10 mRNA
expression and serum levels are elevated in gastric carcinogenesis,
particularly in the advanced stage [10,12,26,27]. The role that
IL10 plays in carcinogenesis may be due to its ability to act not
Table 2. The Association between IL10 Genetic Variants and the Risk of Gastric Cancer, Stratified by Histological Type of Noncardia
Gastric Cancer.
All type Intestinal type (n=253) Diffuse type (n=214)
No. of
Controls
(%)
No. of
Cases (%)
Crude OR
(95% CI)
Multivariate
OR (95% CI)
*
No. of
Cases (%)
Crude OR
(95% CI)
Multivariate
OR (95% CI)
*
No. of
Cases (%)
Crude OR
(95% CI)
Multivariate
OR (95% CI)
*
IL10-1082
AA 435 (87.9) 416 (84.0) 1.0 1.0 209 (82.6) 1.0 1.0 182 (85.1) 1.0 1.0
G carrier 60 (12.1) 79 (16.0) 1.37 (0.92, 1.99) 1.42 (0.96, 2.10) 44 (17.4) 1.59 (1.01, 2.51) 1.69 (1.06, 2.69) 32 (14.9) 1.30 (0.80, 2.03) 1.18 (0.71, 1.96)
IL10-592
{
AA 248 (50.1) 231 (46.7) 1.0 (Ref) 1.0 107 (42.29) 1.0 1.0 102 (47.7) 1.0 1.0
C carrier 247 (49.9) 264 (53.3) 1.15 (0.89, 1.47) 1.20 (0.91, 1.57) 146 (57.71) 1.37 (1.01, 1.86) 1.55(1.10, 2.18) 112 (52.3) 1.10 (0.80, 1.52) 1.18 (0.83, 1.67)
Haplotype
{
ATA 687 (69.4) 676 (68.3) 1.0 (Ref) 1.0 (Ref) 332 (65.6) 1.0 (Ref) 1.0 (Ref) 294 (68.7) 1.0 (Ref) 1.0 (Ref)
ACC 239 (24.1) 228 (23.0) 0.97 (0.79, 1.20) 0.98 (0.78, 1.23) 126 (24.9) 1.09 (0.85, 1.40) 1.14 (0.87, 1.51) 99 (23.1) 0.97 (0.74, 1.27) 1.01 (0.75, 1.37)
GCC 64(6.5) 86 (8.7) 1.37 (0.97, 1.92) 1.39 (0.96, 2.00) 48 (9.5) 1.55 (1.04, 2.31) 1.64 (1.06, 2.54) 35 (8.2) 1.28 (0.83, 1.97) 1.15 (0.71, 1.85)
Abbreviations: OR, odds ratio; CI, confidence interval.
*Adjusted for age, sex, H. pylori infection, smoking status, alcohol consumption, education, and income.
{IL10-819 and IL10-592 were in complete linkage disequilibrium.
{composed of three polymorphic sites; -1082A/G, -819T/C, and -592A/C.
doi:10.1371/journal.pone.0029643.t002
Table 3. The Effects of Helicobacter Infection Status on the Association between IL10 Genetic Variants and the Risk of Noncardia
Gastric Cancer, Stratified by Histological Type*.
All type Intestinal type Diffuse type
H. Pylori (-) H. Pylori (+) H. Pylori (-) H. Pylori (+) H. Pylori (-) H. Pylori (+)
All genotypes No. of controls/cases 165/50 329/443 165/27 329/225 165/20 329/194
OR (95% CI)
* 1.0 (ref) 4.30(3.02, 6.11) 1.0 (ref) 3.91(2.49, 6.16) 1.0 (ref) 4.84(2.92, 8.03)
IL10-1082
AA No. of controls/cases 147/42 287/372 147/23 287/185 147/16 287/166
OR (95% CI)
* 1.0 (ref) 4.21(2.89, 6.14) 1.0(ref) 3.64(2.24, 5.91) 1.0(ref) 5.42(3.09, 9.50)
G carrier No. of controls/cases 18/8 42/71 18/4 42/40 18/4 42/28
OR (95% CI)
* 1.46(0.59, 3.64) 5.59(3.33, 9.41) 1.25(0.38, 4.11) 6.02(3.18, 11.42) 2.13(0.62, 7.27) 5.54(2.69, 11.41)
P for interaction=0.786 P for interaction=0.705 P for interaction=0.365
IL10-592
{
AA No. of controls/cases 75/25 172/206 75/15 172/92 75/7 172/95
OR (95% CI)
* 1.0 (ref) 3.21(2.03, 5.44) 1.0 (ref) 2.28(1.22, 4.24) 1.0(ref) 6.48 (2.84, 14.81)
C carrier No. of controls/cases 90/25 157/237 90/12 157/133 90/13 157/99
OR (95% CI)
* 0.82(0.43, 1.54) 4.25(2.59, 6.95) 0.66(0.29, 1.51) 4.04(2.19, 7.46) 1.80(0.67, 4.81) 7.23(3.17, 16.52)
P for interaction=0.306 P for interaction=0.047 P for interaction=0.394
*Adjusted for age, sex, smoking status, alcohol consumption, education, and income.
{IL10-819 and IL10-592 were in complete linkage disequilibrium.
doi:10.1371/journal.pone.0029643.t003
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suppressant [28]. H. pylori-induced IL10 production, while having
beneficial effects in terms of limiting the tissue damage caused by
inflammation, may also render mucosal immune cells unable to
adequately defense against malignant cells [25]. Therefore, the
higher levels of IL10 found in the IL10 genetic variants carriers
Table 4. The Effects of Smoking Status on the Association between IL10 Genetic Variants and the Risk of Noncardia Gastric Cancer,
Stratified by Histological Type*.
Non-smoker Past smoker Current smoker
All type All genotypes No. of controls/cases 208/138 158/108 129/204
OR (95% CI)
* 1.0 (ref) 1.05 (0.66, 1.66) 2.45 (1.58, 3.80)
IL10-1082
AA No. of controls/cases 180/155 140/191 115/170
OR (95% CI)
* 1.0 (ref) 1.00 (0.62, 1.61) 2.23 (1.41, 3.50)
G carrier No. of controls/cases 28/28 18/17 14/34
OR (95% CI)
* 1.05 (0.57, 1.93) 1.41 (0.64, 3.12) 4.76 (2.20, 10.30)
P for interaction=0.323
IL10-592
{
AA No. of controls/cases 105/90 72/46 71/95
OR (95% CI)
* 1.0 (ref) 0.89 (0.49, 1.61) 2.06 (1.20, 3.55)
C carrier No. of controls/cases 103/93 86/62 58/109
OR (95% CI)
* 1.00 (0.65, 1.53) 1.16 (0.67, 2.03) 2.88 (1.67, 4.95)
P for interaction=0.541
Intestinal type All genotypes No. of controls/cases 208/64 158/71 129/118
OR (95% CI)
* 1.0 (ref) 1.54 (0.87, 2.71) 3.66 (2.12, 6.36)
IL10-1082
AA No. of controls/cases 180/55 140/59 115/95
OR (95% CI)
* 1.0 (ref) 1.43 (0.79, 2.59) 3.18 (1.80, 5.61)
G carrier No. of controls/cases 28/9 18/12 14/23
OR (95% CI)
* 1.01 (0.42, 2.41) 2.25 (0.89, 5.66) 8.72(3.64, 20.91)
P for interaction=0.223
IL10-592
{
AA No. of controls/cases 105/26 72/26 71/55
OR (95% CI)
* 1.0 (ref) 1.29 (0.60, 2.77) 3.42 (1.69, 6.94)
C carrier No. of controls/cases 103/38 86/45 58/63
OR (95% CI)
* 1.37 (0.75, 2.51) 2.23 (1.10, 4.51) 5.40 (2.69, 10.84)
P for interaction=0.867
Diffuse type All genotypes No. of controls/cases 208/108 158/29 129/77
OR (95% CI)
* 1.0 (ref) 0.64 (0.35, 1.19) 1.82 (1.06, 3.13)
IL10-1082
AA No. of controls/cases 180/91 140/24 115/67
OR (95% CI)
* 1.0 (ref) 0.59 (0.31, 1.12) 1.73 (0.99, 3.02)
G carrier No. of controls/cases 28/17 18/5 14/10
OR (95% CI)
* 0.91 (0.45, 1.85) 1.00 (0.32, 3.13) 2.56 (0.94, 7.02)
P for interaction=0.577
IL10-592
{
AA No. of controls/cases 105/55 72/13 71/34
OR (95% CI)
* 1.0 (ref) 0.50 (0.22, 1.12) 1.44 (0.73, 2.83)
C carrier No. of controls/cases 103/53 86/16 58/43
OR (95% CI)
* 0.93 (0.56, 1.54) 0.73 (0.34, 1.56) 2.10(1.09, 4.03)
P for interaction=0.459
*The numbers given in the first line for each group are the numbers of controls/cases while the numbers on the second line are the adjusted odds ratios with the 95%
confidence intervals in parenthesis. Adjustments were made for age, sex, and H. pylori infection status, alcohol consumption, education, and income.
{IL10-819 and IL10-592 were in complete linkage disequilibrium.
doi:10.1371/journal.pone.0029643.t004
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during chronic infection. Similarly, the local immunosuppressive
cytokine production in chronic gastritis may predispose individuals
to the development of gastric carcinogenesis [25]. However, the
roles of IL10 and its polymorphisms in the pathogenesis of gastric
cancer require further investigation.
Environmental factors may also play an important role in
gastric carcinogenesis [29]. In the present study, the effects of
smoking seemed to be confined to H. pylori-infected participants,
and a synergistic effect between H. pylori infection and smoking in
terms of increasing the risk of noncardia gastric cancer was
observed. This result is in agreement with the findings of several
previous studies [30,31]. Excessive inflammation in response to H.
pylori infection is associated with an increased vulnerability to
gastric carcinogenesis [5]. The synergistic effect of smoking on the
risk of developing H. pylori-associated cancer may result from
various mechanisms that enhance the deleterious state induced by
the infection. Smokers have elevated levels of circulating
inflammatory mediators, which may exacerbate the detrimental
effects of H. pylori-associated gastric inflammation [8,16,32]. It is
also plausible that the gastric mucosal damage caused by H. pylori-
infection is exacerbated by tobacco carcinogens [33]. The male
predominance of gastric cancer, which is related to a 10- to 15-
year delay in the development of intestinal-type gastric cancer in
females compared to males, may be attributed to the protective
role of estrogens against gastric carcinogenesis [34]. However, in
light of our findings, the higher rates of H. pylori infection and
smoking in adult Korean men compared to women may also
partly explain the male predominance of gastric cancer in the
Korean population [35].
Genetic susceptibility may modify the propensity for gastric
carcinogenesis through an alteration of the inflammatory state and
may also interact with other risk factors. In the present study, the
elevated risk of noncardia gastric cancer in the IL10 variant
carriers was more significant in H. pylori-positive subjects who
smoked, and these results are similar to the findings of a case-
control study in the Taiwanese Chinese population [18]. Another
case-control study conducted in Korea reported that a genotype
that yields high IL10 production was associated with an increased
risk of gastric cancer only within a low soybean intake group,
suggesting that the anti-inflammatory effects of soy may
counterbalance the pro-carcinogenic effects of the IL10 genetic
variants [36]. Taken together, these findings suggest that H. pylori-
positive smokers with genetic susceptibility to gastric cancer may
be an important group to target for prevention and early
detection.
Gastric cancer may have different clinicopathological charac-
teristics based on the anatomic site and histological type [6,37,38].
In the present study, we investigated only noncardia gastric cancer
patients because H. pylori is a strong risk factor for noncardia, but
not cardia, gastric cancer [39,40]. We found that IL10 variant
carriers with high levels of inflammation (H. pylori infection and
smoking) had an increased risk of intestinal-type gastric cancer.
Several studies have reported a differential association between
genetic variants and the histological types of gastric cancer, but the
lack of consistent evidence has hindered the ability to draw any
definitive conclusions [9,23]. Environment and lifestyle are known
to affect the development of intestinal-type cancer more than the
diffuse-type [41]. It is generally accepted that well-differentiated,
intestinal-type gastric cancer develops mostly in older patients
through a multistep process that include chronic inflammation,
atrophy, and intestinal metaplasia [42]. This notion is supported
by our supplemental data that demonstrated that the effects of
environmental factors (H. pylori infection and smoking) and genetic
variants on the risk of advanced atrophy and intestinal metaplasia
were similar to those on intestinal-type gastric cancer (Table S1).
Therefore, improvements in diet and declines in cigarette smoking
and H. pylori infections may have contributed to the decrease in
intestinal/noncardia type gastric cancer in recent years [38,41].
This study contains several limitations that should be consid-
ered. First, the prevalence of H. pylori infection could be
underestimated because histological changes in the stomach
caused by H. pylori might lead to the spontaneous clearance of
the bacteria [43]. Additionally, we could not consider H. pylori
strain variability, which is important because the strains vary in
their carcinogenic potential [44]. However, these limitations are
likely not considerable because previous data have suggested that
the sensitivity and specificity for the H. pylori detection method
used in the present study were both more than 95% in gastric
cancer patients [45] and, in contrast to what is found in Western
populations, CagA seroprevalence has been reported to be greater
than 95% in infected Koreans [46]. Second, this study is a case-
control study. Thus, selection and recall biases may affect the
results. Third, the sample size was relatively small, especially for
the examination of gene-environment interactions in stratified
analyses [47]. Therefore, the near significant interactions between
gene and environmental factors or even the null results should be
interpreted carefully because of our limited power. Finally, several
residual confounding factors may be important to consider. Other
genes and environmental factors (e.g., dietary habits) may act
either alone or in concert with those studied here in the
pathogenesis of gastric cancer. Therefore, studies using a larger
number of subjects from different populations are needed to
elucidate additional gene-gene and gene-environment interactions
in gastric cancer susceptibility [18].
In conclusion, our study found that IL10 related host
susceptibilities may play a role in gastric carcinogenesis at
noncardia locations via an interaction with H. pylori infection
and cigarette smoking. These results support the notion that
gastric carcinogenesis is induced in multiple steps that involve both
genetic and environmental factors. These findings may be helpful
in identifying individuals at an increased risk for developing
noncardia gastric cancer.
Supporting Information
Table S1 Combined Effects of H. pylori Infection and
Smoking on the Association between IL10 Genetic
Variants and the Risk of Advanced Atrophy and
Intestinal Metaplasia in the Antrum and Body of the
Stomach. We evaluated the associations between either intestinal
metaplasia or atrophy [advanced stage (grade 2 + grade 3) vs. early
stage (grade 0 + grade 1)] and IL10 SNPs, and the combined effect
of H. pylori infection and smoking on these associations. The
Figure 1. Effects of Environmental Factors on the Association between IL10 Polymorphisms and the Risk of Noncardia Gastric
Cancer. H. pylori (Hp) infection and smoking (S) were selected as environmental risk factors, and IL10 promoter genetic variants (-1082/-819/-592)
were investigated. Since IL10-819 and -592 were found to be in complete linkage disequilibrium, we presented the data for IL10-1082 (A) and -592 (B).
Noncardia gastric cancer was stratified by histological type. Multiple logistic regression was adjusted for age, sex, alcohol consumption, education,
and income. The significance of the interactions between genetic variants and environmental risk factors was assessed with a likelihood ratio test,
which compared a model that included the interaction term with one that only contained the main effects.
doi:10.1371/journal.pone.0029643.g001
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were in complete linkage disequilibrium.
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